Breaking News Instant updates and real-time market news.

FTI

TechnipFMC

$34.70

0.44 (1.28%)

, TKPPY

Technip

$17.35

0.1 (0.58%)

17:03
12/01/16
12/01
17:03
12/01/16
17:03

FMC Technologies and Technip combination receives clearance in Brazil

FMC Technologies' (FTI) and Technip's (TKPPY) pending combination has received a clearance decision issued by the General Superintendent of the Administrative Council for Economic Defense, the Brazilian antitrust authority. The decision is subject to a 15-day waiting period. Brazil is the last outstanding antitrust clearance required prior to closing. Clearance decisions have previously been provided by antitrust authorities in the U.S., the European Union, India, Turkey, Mexico and Russia. The transaction is expected to close in early 2017, subject to the satisfaction of other closing conditions.

FTI

TechnipFMC

$34.70

0.44 (1.28%)

TKPPY

Technip

$17.35

0.1 (0.58%)

FTI TechnipFMC
$34.70

0.44 (1.28%)

09/22/16
GHSC
09/22/16
DOWNGRADE
Target $28
GHSC
Neutral
FMC Technologies downgraded to Neutral from Accumulate at Seaport Global
Seaport Global analyst Mark Brown downgraded FMC Technologies to Neutral from Accumulate, stating that upstream customers have "little appetite" for deepwater development spending. The analyst lowered his order and earnings forecasts and cut his price target on FMC shares to $28 from $29.
09/22/16
09/22/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CBS (CBS) downgraded to Market Perform from Outperform at Telsey Advisory with analyst Tom Eagan saying that CBS will probably merge with Viacom (VIA, VIAB). 2. Jabil Circuit (JBL) downgraded to Hold from Buy at Needham with analyst Sean Hannan saying that 2017 will unlikely be a "robust year." 3. Pearson (PSO) downgraded to Neutral from Outperform at Exane BNP Paribas. 4. Syntel (SYNT) downgraded to Market Perform from Outperform at Barrington with analyst Vincent Colicchio saying he's "increasingly concerned that the challenging environment will continue to negatively impact the company's business." 5. FMC Technologies (FTI) downgraded to Neutral from Accumulate at Seaport Global wit analyst Mark Brown saying upstream customers have "little appetite" for deepwater development spending. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/20/16
UBSW
10/20/16
UPGRADE
Target $38
UBSW
Buy
FMC Technologies upgraded to Buy from Neutral at UBS
UBS analyst Angie Sedita upgraded FMC Technologies to Buy citing an improved outlook due to an uptick in subsea orders as well as a recovery in surface sales and margins. The stock's valuation has historically expanded with an improved order outlook, Sedita tells investors in a research note. She raised her price target for FMC shares to $38 from $32 following the company's Q3 results.
11/23/16
GRIF
11/23/16
UPGRADE
GRIF
Buy
FMC Technologies upgraded to Buy from Neutral at Griffen Securities
TKPPY Technip
$17.35

0.1 (0.58%)

12/10/15
JEFF
12/10/15
NO CHANGE
JEFF
FMC, Technip combination seems plausible, says Jefferies
Jefferies analyst Brad Handler says a combination of FMC Technologies (FTI) and Technip (TKPPY) seems plausible. Reuters last night reported that the two companies were in talks. The analyst calls a merger of equals logical, but adds he has thought of Technip as the logical acquirer. Either way, the value proposition of the combined company in deepwater development is intriguing, Handler tells investors in a research note. Technip overnight denied it was in talks regarding a possible strategic transaction.
06/17/16
LEHM
06/17/16
DOWNGRADE
LEHM
Underweight
Technip downgraded to Underweight from Equal Weight at Barclays
09/19/16
FBCO
09/19/16
INITIATION
FBCO
Outperform
Technip initiated with an Outperform at Credit Suisse
09/21/16
JANY
09/21/16
DOWNGRADE
Target $36
JANY
Neutral
Janney downgrades Clovis with buyout speculation at 'fever pitch'
Janney Capital analyst Roy Buchanan downgraded Clovis Oncology (CLVS) to Neutral from Buy with an increased fair value estimate of $36. Clovis is up 17c to $35.00 in late morning trading. In a research note partially titled, "May Be Right, May Be Crazy - M&A Speculation At Fever Pitch," Buchanan says there is a "finite chance" that Clovis will need to market its PARP inhibitor rucaparib by itself. He believes a late-2016 approval for rucaparib is likely. The analyst attributes his increased fair value estimate to "acquisition optionality." Reports of Takeda's (TKPYY) reserving up to $15B for acquisitions and Medivation's (MDVN) takeout have given Clovis shares a lift, Buchanan tells investors. The analyst adds that rumors surfaced yesterday of potential interest in the company from Eli Lilly (LLY).

TODAY'S FREE FLY STORIES

SPEX

Spherix

$1.00

-0.0013 (-0.13%)

08:14
06/27/17
06/27
08:14
06/27/17
08:14
Hot Stocks
Spherix issues letter to shareholders on Hoth transaction »

Spherix issued a letter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCR

NCR Corp.

$40.15

1.51 (3.91%)

08:13
06/27/17
06/27
08:13
06/27/17
08:13
Hot Stocks
MFA Oil implements NCR OPTIC 5 solution across 73 locations »

NCR Corporation announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMTX

Dimension Therapeutics

$1.55

0.1 (6.90%)

08:13
06/27/17
06/27
08:13
06/27/17
08:13
Hot Stocks
Dimension Therapeutics completes strategic review, updates corporate priorities »

Dimension Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTY

Getty Realty

$25.05

0.21 (0.85%)

08:11
06/27/17
06/27
08:11
06/27/17
08:11
Hot Stocks
Getty Realty enters definitive agreement to acquire 49 properties for $123M »

Getty Realty announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XENE

Xenon Pharmaceuticals

$3.80

-0.3 (-7.32%)

08:10
06/27/17
06/27
08:10
06/27/17
08:10
Hot Stocks
Breaking Hot Stocks news story on Xenon Pharmaceuticals »

Xenon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABIL

Ability

$1.40

0.14 (11.11%)

08:09
06/27/17
06/27
08:09
06/27/17
08:09
Hot Stocks
Ability regains Nasdaq listing compliance »

Ability received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VCYT

Veracyte

$7.90

0.14 (1.80%)

08:09
06/27/17
06/27
08:09
06/27/17
08:09
Hot Stocks
Veracyte says study published supporting Envisia Genomic Classifier »

Veracyte announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$53.74

-0.59 (-1.09%)

08:08
06/27/17
06/27
08:08
06/27/17
08:08
Recommendations
PayPal analyst commentary  »

PayPal could free up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

RCII

Rent-A-Center

$11.48

0.28 (2.50%)

08:08
06/27/17
06/27
08:08
06/27/17
08:08
Hot Stocks
Rent-A-Center names Martin Evans chief human resources officer »

Rent-A-Center announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$248.91

2.45 (0.99%)

08:07
06/27/17
06/27
08:07
06/27/17
08:07
Hot Stocks
Allergan launches Refresh Optive Mega-3 artificial tears »

Allergan launched the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSTG

Biostage

$0.34

0.025 (7.94%)

08:07
06/27/17
06/27
08:07
06/27/17
08:07
Syndicate
Biostage raises $3.1M in a private placement »

Biostage announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBVX

MabVax Therapeutics

$1.46

-0.0775 (-5.04%)

08:06
06/27/17
06/27
08:06
06/27/17
08:06
Hot Stocks
MabVax Therapeutics begins dosing in Phase 1 clinical trial evaluating MVT-1075 »

MabVax Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPLD

Upland Software

$22.29

-0.21 (-0.93%)

08:06
06/27/17
06/27
08:06
06/27/17
08:06
Initiation
Upland Software initiated  »

Upland Software initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVIV

InVivo Therapeutics

$2.55

-0.3 (-10.53%)

08:05
06/27/17
06/27
08:05
06/27/17
08:05
Hot Stocks
InVivo Therapeutics announces new patient enrollment in INSPIRE study »

InVivo Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

PHG

Philips

$36.74

-0.12 (-0.33%)

08:04
06/27/17
06/27
08:04
06/27/17
08:04
Hot Stocks
Philips receives FDA 510(k) clearance to market IntelliSpace Portal 9.0 »

Royal Philips announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$90.08

1.35 (1.52%)

08:03
06/27/17
06/27
08:03
06/27/17
08:03
Technical Analysis
Technical View: Darden trades near 52-week high after earnings »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 18

    Jul

  • 19

    Jul

KSS

Kohl's

$37.52

0.49 (1.32%)

, SVU

Supervalu

$3.03

0.09 (3.06%)

08:03
06/27/17
06/27
08:03
06/27/17
08:03
Hot Stocks
Kohl's appoints Bruce Besanko as CFO »

Kohl's (KSS)…

KSS

Kohl's

$37.52

0.49 (1.32%)

SVU

Supervalu

$3.03

0.09 (3.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$65.92

-0.24 (-0.36%)

, SNY

Sanofi

$49.59

0.26 (0.53%)

08:03
06/27/17
06/27
08:03
06/27/17
08:03
Recommendations
Merck, Sanofi, Johnson & Johnson, Bristol-Myers, Pfizer, Roche, Novartis, AstraZeneca, GlaxoSmithKline, Eli Lilly analyst commentary  »

Large cap pharma could…

MRK

Merck

$65.92

-0.24 (-0.36%)

SNY

Sanofi

$49.59

0.26 (0.53%)

JNJ

Johnson & Johnson

$136.34

-0.09 (-0.07%)

BMY

Bristol-Myers

$56.92

0.28 (0.49%)

PFE

Pfizer

$34.04

-0.13 (-0.38%)

RHHBY

Roche

$32.47

-0.29 (-0.89%)

NVS

Novartis

$85.75

-0.59 (-0.68%)

AZN

AstraZeneca

$35.15

0.08 (0.23%)

GSK

GlaxoSmithKline

$44.07

-0.22 (-0.50%)

LLY

Eli Lilly

$84.28

0.39 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 11

    Jul

  • 12

    Jul

  • 13

    Jul

  • 18

    Jul

  • 27

    Jul

  • 30

    Jul

  • 02

    Aug

  • 27

    Aug

  • 22

    Sep

  • 24

    Sep

NFEC

NF Energy

$0.92

0.01 (1.10%)

08:02
06/27/17
06/27
08:02
06/27/17
08:02
Hot Stocks
NF Energy signs $600K valve sales contract »

NF Energy signed a $600K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROV

Trovagene

$1.12

-0.02 (-1.75%)

08:02
06/27/17
06/27
08:02
06/27/17
08:02
Hot Stocks
Trovagene submits IND application to FDA for Phase 1b/2 trial of PCM-075 »

Trovagene announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWKS

Skyworks

$101.32

-3.04 (-2.91%)

08:00
06/27/17
06/27
08:00
06/27/17
08:00
Options
Skyworks put buyer realizes 14% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHAK

Shake Shack

$35.54

-1.46 (-3.95%)

07:59
06/27/17
06/27
07:59
06/27/17
07:59
Recommendations
Shake Shack analyst commentary  »

Shake Shack Q2 comps may…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MON

Monsanto

$117.80

0.78 (0.67%)

, BAYRY

Bayer

$136.70

0.34 (0.25%)

07:56
06/27/17
06/27
07:56
06/27/17
07:56
Downgrade
Monsanto, Bayer rating change  »

Monsanto downgraded to…

MON

Monsanto

$117.80

0.78 (0.67%)

BAYRY

Bayer

$136.70

0.34 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

07:55
06/27/17
06/27
07:55
06/27/17
07:55
General news
U.S. chain store sales climbed 2.9% in the week ended June 24 »

U.S. chain store sales…

RARX

RA Pharmaceuticals

$22.18

-0.83 (-3.61%)

07:55
06/27/17
06/27
07:55
06/27/17
07:55
Conference/Events
RA Pharmaceuticals to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.